Integrated Diagnostics
The year saw the launch of high-profile platforms as well as efforts by a number of parties to streamline mass spec technologies for the clinic.
The company is confident about bringing the test to market despite potential future competition and views it as an easy fit for its existing sales channels.
Biodesix Acquires Integrated Diagnostics
The deal gives Biodesix an additional test in the lung cancer space, Indi's XL2, which helps to classify lung nodules identified by imaging scans as benign or malignant.
According to a study author, the findings indicate the test could be useful for assessing indeterminate lung lesions, but clinical utility data is still needed.
In Brief This Week: BioMérieux, Integrated Diagnostics, BioAffinity Technologies, And More
ioMérieux this week released consolidated financial statements for the year ended Dec. 31, 2017, confirming the earnings it reported in January.